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Abstract
Solid organ transplant recipients have increased risk for developing keratinocyte cancers (KC), 
including cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a 
result of immunosuppressive medications administered to prevent graft rejection. In the general 
population, KC are associated with increased risks of subsequent malignancy, however, the risk in 
organ transplant populations has not been evaluated. We addressed this question by linking the 
U.S. Scientific Registry of Transplant Recipients, which includes data on KC occurrence, with 15 
state cancer registries. Risk of developing malignancies after KC was assessed among 118,440 
Caucasian solid organ transplant recipients using multivariate Cox regression models. Cutaneous 
SCC occurrence (n=6169) was associated with 1.44-fold increased risk [95% confidence interval 
(CI): 1.31–1.59] for developing later malignancies. Risks were particularly elevated for non-
cutaneous SCC, including those of the oral cavity/pharynx [hazard ratio (HR)=5.60, 95%CI: 4.18–
7.50] and lung (HR=1.66, 95%CI: 1.16–2.31). Cutaneous SCC was also associated with increased 
risk of human papillomavirus-related cancers, including anal cancer (HR=2.77, 95%CI: 1.29–
5.96) and female genital cancers (HR=3.43, 95%CI: 1.44–8.19). In contrast, BCC (n=3669) was 
not associated with overall risk of later malignancy (HR=0.98, 95%CI: 0.87–1.12) including any 
SCC. Our results suggest that transplant recipients with cutaneous SCC, but not BCC, have an 
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increased risk of developing other SCC. These findings somewhat differ from those for the general 
population and suggest a shared etiology for cutaneous SCC and other SCC in the setting of 
immunosuppression. Cutaneous SCC occurrence after transplantation could serve as a marker for 
elevated malignancy risk.
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Introduction
Keratinocyte carcinomas (KCs), including cutaneous squamous cell carcinoma (SCC) and 
basal cell carcinoma (BCC), are the most common malignancy in the United States (1). In 
the general population, BCC is more common than SCC, accounting for about 80% of all 
KC diagnoses (2). Exposure to ultraviolet radiation (UVR) is the primary risk factor for both 
SCC and BCC (2,3). Although BCC and SCC are rarely fatal, they can metastasize, and 
patients with metastatic SCC have poor prognoses (2). Individuals in the general population 
with a history of KC have increased risk of developing a variety of cancers, including 
melanoma, oral cancers, and non-Hodgkin lymphoma (NHL) (4–8).
Solid organ transplant recipients have greatly increased risk of KC compared with the 
general population (9), with estimated risks increased over 100-fold for SCC and 10-fold for 
BCC (10–12). KC risk is related to the use of immunosuppressive drugs to prevent rejection 
of transplanted organs, with higher risks seen in those recipients who receive higher levels of 
immunosuppressive therapy (13) and for longer durations (12). Solid organ transplant 
recipients are also at elevated risk of developing a range of other malignancies throughout 
the body (14,15). Overall risk of new malignancy after solid organ transplantation is 
approximately two-fold higher than in the general population, though increases for specific 
infection-related malignancies including NHL, anogenital cancers, and Kaposi sarcoma are 
even higher (14–20).
In 2015, 30,973 people underwent solid organ transplantation in the United States, and 
approximately 300,000 organ transplant recipients were alive with a functioning transplanted 
organ in 2014 (21). Because transplant recipients have unique exposures due to risk factors 
for transplant and immunosuppressive treatment and high risk for developing new 
malignancies, prior studies on the risk of malignancy following KC may not be 
generalizable to transplant recipients. We therefore utilized a large-scale, population-based 
study to describe the risk of malignancy following cutaneous BCC or SCC in 118,440 
individuals who received a solid organ transplant during 1987–2011.
Methods
Study population and transplantation data
The Transplant Cancer Match Study, described in detail previously (14), links the Scientific 
Registry of Transplant Recipients (SRTR) with population-based cancer registries to provide 
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systematic ascertainment of malignancy among solid organ transplant recipients in the 
United States. Sixteen registries were included in the analysis: the states of California (years 
of data inclusion with ≥95% complete case ascertainment, 1988–2008), Colorado (1988–
2009), Connecticut (1973–2009), Florida (1981–2009), Georgia (1995–2010), Hawaii 
(1973–2007), Iowa (1973–2009), Illinois (1986–2007), Kentucky (1995–2011), Michigan 
(1985–2009), North Carolina (1990–2010), New Jersey (1979–2010), New York (1976–
2010), Texas (1995–2010), and Utah (1973–2008), as well as the Seattle/Puget Sound area 
of Washington State (1974–2008). The SRTR includes information on all solid organ 
transplants in the United States starting in 1987. For this analysis, data derived from the 
SRTR included basic demographic and transplantation data, health information at the time of 
transplantation [body-mass index (BMI), history of diabetes, Epstein-Barr virus (EBV) 
antibody status], and baseline data on receipt of specific types of induction and maintenance 
immunosuppressive medications to prevent graft rejection (Table 1).
The study population included first transplant recipients who resided in participating cancer 
registry catchment areas. We excluded individuals who had a transplant prior to the 
beginning of registry coverage (n=6,156), had a cancer diagnosis other than KC or in situ 
cancer reported to a cancer registry preceding the transplant (n=13,242), were diagnosed 
with liver cancer <6 months after liver transplantation (because these were likely prevalent 
cancers; n=719) (14), or were known to be infected with human immunodeficiency virus 
(HIV) at the time of transplantation (n=96). In addition, because over 95% of KC diagnoses 
occurred among whites, we excluded non-white individuals (n=78,309). The final analytic 
population included 118,440 white individuals with a first transplant, followed during 1987–
2011.
Although UVR exposure is an important determinant of KC risk, we had no individual 
measures of exposure to UVR. We therefore used ambient UVR linked to residence at the 
time of entry onto the transplant waitlist or at transplantation as a proxy for UVR exposure. 
Residential zip codes were linked to the National Aeronautics and Space Administration 
(NASA) Total Ozone Mapping Spectrometer (TOMS) database, which provides satellite-
based estimates of ambient cloud-adjusted UVR on a 1° latitude by 1° longitude grid (22). 
We averaged daily at noontime between 1982 and 1992 to account for fluctuations in the 11-
year solar cycle. UVR exposure was grouped into quartiles based on the study population 
distribution at baseline.
BCC and SCC ascertainment
Occurrence of KC (BCC and SCC) is not captured by cancer registries but is ascertained in 
transplant recipients based on patient medical records, as reported in yearly transplant center 
follow-up reports included in the SRTR. We validated SRTR data on KC diagnoses using 
Medicare claims for the subset of Medicare-eligible individuals (23). We found that 14% of 
BCC cases and 22% of SCC cases reported to Medicare were captured by the SRTR 
(Supplementary Table S1), indicating low sensitivity. However, 71% of the BCCs and 73% 
of the SCCs in the SRTR were confirmed by Medicare claims, indicating a high positive 
predictive value of SRTR-documented KCs.
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Data for cancers other than KCs were obtained from the 15 linked cancer registries. 
Malignant cancers were coded according to the International Classification of Diseases for 
Oncology, 3rd edition (ICD-O-3) (Supplementary Table S2) (1). We considered risk for 
malignancy overall as well as specific types or groupings that occurred in at least 100 
recipients in our study population. Non-KC skin cancers are captured by cancer registries, 
and thus were evaluated in this analysis as a cancer outcome. Morphology codes further 
distinguished squamous and non-squamous oral cavity/pharyngeal, esophageal, lung, and 
bladder cancers; diffuse large B-cell lymphoma from other NHLs; and Merkel cell 
carcinoma from other types of non-KC skin cancer (Table 2 footnote, most commonly 
sebaceous adenocarcinoma, dermatofibrosarcoma, and malignant fibrous histiocytoma).
Statistical analysis
Follow-up began on the date of transplantation and ended at the first of: cancer registry 
cancer diagnosis, graft failure, re-transplantation, loss to follow-up, end of registry coverage, 
or death. We first estimated the relative risk of developing BCC or SCC among transplant 
recipients in association with key demographic and transplant-related factors using hazard 
ratios (HRs) and 95% confidence intervals (CIs) derived from Cox regression analyses with 
age as the time scale. As specified a priori, models were adjusted for sex, year of 
transplantation, type of organ transplanted, and time since transplantation (as a time-
dependent covariate). Using similar models, we then estimated the relative risk of 
developing cancer after KC among transplant recipients. The occurrences of BCC and SCC 
were each included in the model as time-dependent variables, recording the first instance of 
each type of KC.
Additional potential confounders evaluated were BMI, diabetes, induction medications, 
baseline maintenance medications, and ambient UVR quartiles. However, inclusion of these 
factors did not meaningfully change (>10%) the BCC or SCC risk estimates, thus they were 
excluded from the final models. We also conducted secondary analyses with three time-
dependent covariates for KC occurrence: BCC only, SCC only, and both BCC + SCC in 
order to assess potential differences in risk among individuals who developed both BCC and 
SCC compared to BCC alone or SCC alone. Individuals who developed BCC before SCC 
were included in the BCC only group until the development of SCC, and vice-versa for 
those who developed SCC before BCC.
Analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
The majority of 118,440 solid organ transplant recipients in our study population were male 
(62.6%), and the most commonly transplanted organ was kidney (51.5%) followed by liver 
(21.9%) (Table 1). The median age at transplantation was 49 years. Following 
transplantation, a total of 8056 recipients developed KC, including 3669 with BCC and 6169 
with SCC (1782 recipients developed both).
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As shown in Table 1, the proportion of individuals who developed KC increased with 
increasing age at transplantation. Males had higher KC risk than females, and risk increased 
with more recent year of transplantation. Liver recipients had the lowest risk of KC, and 
lung recipients had the highest risk, with the elevated risk among lung recipients particularly 
evident for SCC. Receipt of monoclonal antibodies was also associated with increased KC 
risk, whereas inverse associations were observed among individuals receiving maintenance 
therapy with mTOR inhibitors, as well as among individuals with diabetes. UVR exposure 
was also associated with increased risk of KC.
After adjustment for sex, type of organ transplanted, year of transplantation, and follow-up 
time, recipients with SCC after transplantation had 1.44-fold (95%CI 1.31–1.59) increased 
overall risk of developing a new malignancy compared with recipients without SCC (Table 
2). Cancers of the oral cavity/pharynx were the most common malignancy among 
individuals with SCC (n=155), with risk increased 5.34-fold (95%CI: 4.02–7.08). When 
considering histologic subtypes of oral cavity/pharyngeal cancers, associations were 
somewhat stronger for squamous than for non-squamous cancers (n=475, HR=5.60, 95%CI: 
4.18–7.50 versus n=45, HR=3.00, 95%CI: 1.01–8.93). When considering subsite within the 
oral cavity, the associations were consistent for SCC of the lip (HR=4.13, 95%CI: 2.43–
7.00) and tongue (HR=3.58, 95%CI: 1.82–7.05). A reported diagnosis of cutaneous SCC 
after transplantation also was associated with an increased risk of SCC of the lung 
(HR=1.66, 95%CI: 1.16–2.37), but not non-squamous cell lung cancer (HR=1.00, 95%CI: 
0.71–1.39). Other sites with increased risk after a diagnosis of cutaneous SCC included anal 
cancer (HR=2.77, 95%CI: 1.29–5.96), human papillomavirus (HPV)-related female genital 
cancers (defined as cancer of the cervix, vulva, or vagina) (HR=3.43, 95%CI 1.44–8.19), 
melanoma (HR=1.75, 95%CI: 1.17–2.62), Merkel cell carcinoma (HR=3.58, 95%CI: 1.96–
6.53), and other non-epithelial skin cancers (not including Merkel cell carcinoma, 
melanoma, BCC, or SCC) (HR=3.78, 95%CI: 2.17–6.59). Finally, diagnosis of cutaneous 
SCC after transplantation was inversely associated with NHLs other than DLBCL 
(HR=0.41, 95%CI: 0.19–0.89), whereas there was no significant association for DLBCL 
(HR= 1.13, 95%CI: 0.72–1.80).
In contrast to the risk patterns observed for cutaneous SCC, a diagnosis of BCC after 
transplantation was not associated with overall cancer risk (HR=0.98, 95%CI: 0.87–1.12) 
(Table 2). However, associations were observed for several specific malignancies. The 
highest significantly elevated risk occurred for Merkel cell carcinoma (HR=2.10, 95%CI: 
1.05–4.22), whereas there was no significant association for melanoma (HR=1.35, 95%CI: 
0.82–2.22). Among individuals who had a diagnosis of BCC after transplantation, risk was 
borderline elevated for prostate cancer (HR=1.37, 95%CI: 1.01–1.87) and was decreased for 
oral cavity/pharyngeal cancers and colon cancers (Table 2). Risk for non-squamous oral 
cavity/pharyngeal cancers was elevated, but the increased risk was not statistically 
significant (HR=3.07, 95%CI: 0.96–9.80).
In secondary analyses that considered separately risks after BCC only, SCC only, and BCC
+SCC, findings for SCC were largely unchanged, but the inverse associations with BCC 
were no longer evident (Supplementary Table S3). Additional models adjusted for potential 
confounders (BMI, diabetes, EBV serostatus, induction medications, maintenance 
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medications, and UVR exposure) and models that stratified by transplanted organ (kidney, 
liver, heart, other) resulted in no meaningful change in the associations between BCC or 
SCC for any of the subsequent cancer outcomes (data not shown). As a sensitivity analysis, 
we evaluated the association of cutaneous SCC with oral cavity/pharyngeal cancer 
separately for the sites known or suspected to be associated with human papillomavirus 
(HPV; i.e., cancers of the tonsil and oropharynx) versus other sites within the oropharynx; 
both showed increased risk (HR=6.08, 95%CI: 2.69–13.71 and HR=5.20, 95%CI: 3.84–7.03 
respectively).
Discussion
In this study of 118,440 solid organ transplant recipients in the United States, we present 
novel evidence of associations between KC and subsequent malignancy risk, observing 
somewhat different patterns than those observed in the general population. Among 
transplant recipients, risk of overall malignancy was increased after developing cutaneous 
SCC, but not after BCC. Remarkably, risks were specifically elevated after cutaneous SCC 
for a number of other non-cutaneous SCC, including oral cavity/pharyngeal cancers, lip 
cancer, tongue cancer, and lung cancer, whereas BCC was not associated with increased risk 
of any squamous cell cancers. The results suggest a shared carcinogenic mechanism for 
cutaneous SCC and other SCC at different sites in the body among transplant recipients, and 
highlight a population of individuals with increased risk of developing new malignancies. In 
the general population, risk is increased after both BCC and SCC for a wide variety of 
cancers, particularly Hodgkin lymphoma, NHL, and leukemia, as well as overall 
malignancies (4–8). These associations were not evident in our study of transplant 
recipients.
One possible explanation for our findings is that increased risks of both SCC and other 
malignancies are most evident among individuals with higher levels of immunosuppression 
(24–27). However, a number of observations suggest that the degree of immunosuppression 
alone cannot explain our results. First, both induction therapy and organ type are correlated 
with immunosuppression level and were themselves associated with increased risk of KC in 
our study. Nonetheless, the associations of cutaneous SCC with subsequent malignancies 
remained consistent in models adjusted for receipt of induction therapy or stratified by type 
of organ transplanted (data not shown). Second, if cutaneous SCC were solely a marker of 
immunosuppression, we would expect to also see an increased risk of NHL after SCC, since 
risk of NHL is greatly increased with immunosuppression (28,29). Studies in the general 
population also have reported an increased risk of NHL after cutaneous SCC (6). In contrast, 
we found a decreased risk of NHL after cutaneous SCC.
It is plausible that immunosuppression combined with a specific infectious agent, possibly 
HPV, may explain our findings. HPV has been associated with cutaneous SCC in some 
studies (30) and causes cancers of the oropharynx and tonsil, anus, and female genital tract 
(31,32), all of which we observed to be increased after SCC. However, further research is 
needed to explore the potential role of infections in cutaneous SCC and other squamous 
cancers because the association of skin cancers with HPVs is not established, and recent 
evidence supports variation in the observed HPV-cancer associations by HPV genus (33,34). 
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Additionally, we found increased risk of both HPV-related and non-HPV-related oral 
cancers, suggesting that if HPV is playing a role, it is not the only causative factor. Finally, 
lung cancer is not known to be caused by HPV, so this would not explain the increased risk 
of squamous cell lung cancer after cutaneous SCC.
Another possible explanation for our findings is shared germline genetic susceptibility to 
SCC and other squamous cell cancers, including the possibility of susceptibility to DNA 
damaging effects of immunosuppressing medications. Cyclosporine, an immunosuppressing 
drug, has been shown to inhibit DNA repair, which could provide a plausible mechanism for 
these associations (35). However, shared susceptibility among squamous malignancies is 
poorly understood (36). We also did not see associations between cyclosporine or 
azathioprine, which are photosensitizing (37,38), and KC risk.
A potential role for UVR exposure also should be considered in the interpretation of our 
results. UVR induces DNA damage (39), and laboratory studies suggest that skin cancers 
induced by UVR exposure are more likely to grow in immunocompromised hosts (40). 
While it is unlikely that UVR is the mechanism responsible for the increased risk of non-
skin cancers seen in this study, UVR may explain the clustering of BCC and SCC with 
increased risk of melanoma, Merkel cell carcinoma, and other skin cancers (the majority of 
which were either sebaceous carcinoma or fibroxanthoma, data not shown). Similar to BCC 
and SCC, Merkel cell carcinoma is associated with immune deficiency, male predominance, 
older age, and UVR exposure (41,42). While less common, sebaceous carcinoma and 
fibroxanthoma are also associated with immunodeficiency and UVR exposure (43–46). 
However, adjustment for ambient UVR based on residential location did not materially 
change our risk estimates for other cutaneous malignancies after BCC and SCC, possibly 
due to limitations in our UVR exposure measure.
Although primary analyses showed a decreased risk of oral cavity/pharyngeal and colon 
cancers after BCC, these associations were not present in secondary analyses that included 
variables for BCC only, SCC only, and combined BCC+SCC, pointing away from a 
biological relationship with BCC. Instead, one possibility is that once a person develops 
SCC, clinicians may alter a patient’s immunosuppressive regimen (e.g. decreasing the doses, 
or switching to an mTOR inhibitor), which may reduce subsequent risk for non-skin cancers 
(47,48). In contrast, the increased risks after SCC were not meaningfully different in 
secondary analyses.
The primary limitation of our study was the reliance on SRTR data for ascertainment of KC 
diagnoses. Our comparisons with Medicare claims demonstrated that KC reports in the 
SRTR are likely to be valid cases, although the majority of KC cases are not captured in the 
SRTR. Because this under-reporting would likely bias the risk estimates toward the null 
hypothesis, our risk estimates are likely conservative, and we may have missed additional 
significant associations. Although we restricted analyses to cancers with at least 100 cases 
(excluding salivary gland tumors, e.g.), false negative findings are possible due to low power 
for rare cancers or associations with only weakly elevated risks. Additionally, cancer risks 
may have been under-ascertained due to patient migration outside cancer registry areas or 
failure of linkage, though this under-ascertainment is likely to have been small (49,50). False 
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positive results also are possible due to multiple comparisons, and chance could explain 
some borderline associations. Finally, we lacked information on smoking history, which is 
related to SCC (51). and our UVR exposure metric was limited because it reflected 
residence at the time of transplant, rather than during childhood (52), and we lacked 
information on sun sensitivity factors (e.g., Fitzpatrick skin type), time spent outdoors, or 
sun shielding behaviors, though UVR is unlikely to confound non-cutaneous cancer risk 
estimates.
The strengths of this study include a large sample size from around the United States 
representing a wide age range and several types of organ transplants, as well as reliable and 
complete cancer ascertainment based on cancer registry diagnoses. We also had histologic 
information, which allowed us to consider cutaneous SCC and BCC separately and 
differentiate cancer outcomes by squamous cell versus non-squamous cell histology. The 
availability of UVR exposure data, although imperfect, is also a strength of this study.
In this large, population-based study of solid organ transplant recipients in the United States, 
we found that SCC increased risk for additional cancers more so than BCC, and remarkably, 
cutaneous SCC increased risk for other squamous cell cancers whereas BCC did not. In the 
general population, many types of cancer besides squamous cell cancers are increased after 
cutaneous SCC, suggesting that the increase in squamous cell cancers after SCC is unique to 
transplant recipients or those who are immunosuppressed. These results support shared risk 
factors and common carcinogenic mechanisms in cutaneous SCC and other squamous cell 
cancers in immunosuppressed individuals, and that a diagnosis of SCC in transplant 
recipients could potentially serve as a marker for elevated risk for developing certain 
malignancies. Future studies should focus on clarifying potential shared risk factors of all 
squamous cell cancers and identifying optimal prevention and surveillance guidelines for 
KCs and other cancers in solid organ transplant recipients.
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